Skip to content

Author

Haixiang Qi

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Jul 2026

A patent review of mutant-selective PI3Kα inhibitors for the treatment of different cancers (2021 - 2025).

This review evaluates patents of PI3Kα mutant-selective inhibitors disclosed between 2021 and 2025 and examines the binding modes across two distinct allosteric domains: an H1047R-specific pocket (exemplified by Eli Lilly's inhibitors) and a pan-mutant cryptic site (engaged by RLY-2608 and STX-478).

Haixiang Qi, Jiayang Wen, Heng Xu · 0 citations